| |
|
CHAIR |
 |
Ira M. Jacobson, MD
Vincent Astor Professor of
Clinical Medicine
Chief, Division of
Gastroenterology
and Hepatology
Medical Director of the Center
for the Study of Hepatitis C
Weill Cornell Medical College
New York, New York
|
|
MODERATOR
|
 |
Ira Flatow
Executive Producer/Host
Talk of the Nation: Science Friday®
New York, New York
|
|
FACULTY
|
 |
Hashem B. El-Serag, MD, MPH
Professor of Medicine
Department of Gastroenterology
Baylor College of Medicine
and Houston VA Medical Center
Houston, Texas
|
|
 |
Fred Poordad, MD
Chief, Hepatology and Liver
Transplantation
Associate Professor of Medicine
Comprehensive Transplant
Center
Cedars-Sinai Medical Center
Los Angeles, California
|
|
 |
Zobair M. Younossi, MD, MPH
Executive Director of Research,
Inova Health System
Executive Director, Center for Liver
Diseases, Inova Fairfax Hospital
Professor of Medicine,
VCU-Inova Campus
Affiliate Professor of Biomedical Sciences
George Mason University
Falls Church, Virginia |
|
PROGRAM OVERVIEW
This stimulating and thought-provoking webcast features a renowned faculty panel—led by Ira Jacobson, MD—who shape their experience and the latest research data into presentations that clarify the state of the science. Moderating is Ira Flatow, host of Talk of the Nation: Science Friday® on National Public Radio, who practices his notable art of transforming science into discussion. The result: science made useable, complexity made manageable.
|
AGENDA
|
Introduction
Ira Flatow
Ira M. Jacobson, MD |
Reducing the Health Burden of HCV: Moving from Efficacy to Effectiveness
Hashem B. El-Serag, MD, MPH |
Panel Discussion/Q&A
Ira Flatow/Faculty Panel |
Why Is Standard of Care Falling Short?
Zobair M. Younossi, MD, MPH |
Panel Discussion/Q&A
Ira Flatow/Faculty Panel |
Challenges Posed by Nonresponders and Relapsers
Fred Poordad, MD |
Panel Discussion/Q&A
Ira Flatow/Faculty Panel |
Can We Do Better? Role of Emerging STAT-C Drugs
Ira M. Jacobson, MD |
Panel Discussion/Q&A
Ira Flatow/Faculty Panel |
Closing Remarks
Ira M. Jacobson, MD |
| Meeting Adjourns |
top
TARGET AUDIENCE
This CME/CE activity is designed for gastroenterologists, hepatologists, and other clinicians who treat patients with HCV infection.
ACTIVITY GOAL
The goal of this CME/CE activity is to present state-of-the-science, clinically relevant information that will provide clinicians with new insights into managing hepatitis C infection, including scope of disease burden, goals of therapy, barriers to treatment and response, and potential role of emerging specifically-targeted antiviral therapies for HCV.
top
LEARNING OBJECTIVES
- Evaluate standard-of-care therapies and their shortcomings in the treatment and management of HCV infection in order to optimize viral eradication in HCV-infected patients, thereby reducing disease burden.
- Identify factors associated with nonresponse, null response, and relapse in patients receiving anti-HCV treatment in order to select and apply strategies that improve treatment response.
- Assess the potential of emerging HCV therapeutic strategies for improving treatment response and outcomes in HCV-infected patients by analyzing preliminary efficacy and safety data of the protease and polymerase inhibitors.
top
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
EduPro Resources LLC is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number P208-8/08-11.
EduPro Resources LLC is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-14387.
This activity is accredited for 1.86 contact hours.
Disclaimer
Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or EduPro Resources LLC.
Co-Provider Statement
This activity is co-provided by Projects In Knowledge and EduPro Resources LLC.
CE Information: Pharmacists
 Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.5 contact hours (.15 CEUs). The ACPE Universal Program Number assigned to this activity is 052-000-08-061-H01-P.
Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the Contract for Mutual Responsibility in CME/CE, please click here. |
top
DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians’ Desk Reference (PDR).
Hashem B. El-Serag, MD, MPH, has received grant/research support from AstraZeneca and Schering-Plough Pharmaceuticals Corporation; is a consultant for Vertex Pharmaceuticals, Inc; and is on the advisory boards of AstraZeneca and Vertex Pharmaceuticals, Inc. Dr. El-Serag will not be referencing any unlabeled/unapproved uses of drugs or devices in this presentation.
Ira Flatow has no significant relationships to disclose.
Ira M. Jacobson, MD, has received grant/research support from Coley Pharmaceuticals, Gilead Sciences, Inc, GlobeImmune, Human Genome Sciences, Idenix Pharmaceuticals, InterMune Inc, Novartis Pharmaceuticals Corporation, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals, Inc; is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Coley Pharmaceuticals, Dynavax Technologies Corporation, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Human Genome Sciences, Idenix Pharmaceuticals, InterMune Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Nucleonics Inc, Pfizer Inc, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals, Inc; and is on the speakers bureaus of Bristol-Myers Squibb, Gilead Sciences, Inc, Idenix Pharmaceuticals, and Schering-Plough Corporation. Dr. Jacobson will be discussing novel treatments for HCV, some or all of which may be unlabeled or unapproved for use in the treatment of patients with HCV.
Fred Poordad, MD, has received grant/research support from Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, Intarcia Therapeutics, Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals, Inc; is a consultant for Gilead Sciences, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals, Inc; is on the speakers bureau of Gilead Sciences, Inc, and Schering-Plough Corporation; and is on the advisory boards of Gilead Sciences, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals, Inc. Dr. Poordad will be referencing unlabeled/unapproved uses of peginterferon (alfa-2a and -2b), ribavirin, consensus interferon, and colchicine.
Zobair M. Younossi, MD, MPH, FACP, FACG, has received grant/research support from Axcan Pharma, Idenix Pharmaceuticals, Roche Pharmaceuticals, Schering-Plough Corporation, Vertex Pharmaceuticals, Inc, and Wyeth Pharmaceuticals. Dr. Younossi will not be referencing any unlabeled/unapproved uses of drugs or devices in this presentation.
Nancy Nordenson, Content Editor, has no significant relationships to disclose.
Peer Reviewer has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.
This independent CME/CE activity is supported by an educational grant from Vertex Pharmaceuticals Incorporated.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
top
Requires Flash 8 or higher
and high-speed internet
|
|
